Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age greater than or equal to 18 years at the time of signing informed consent~* Diagnosed with type 2 diabetes greater than or equal to 180 days prior to the day of screening~* Treated with basal insulin once daily or twice daily for greater than or equal to 90 days prior to the day of screening~* Stable daily dose for 90 days prior to the day of screening of the following anti-diabetic drugs or combination regimens: Any metformin formulations (greater than or equal to 1500 mg to less than or equal to 3000 mg or maximum tolerated or effective dose documented in subject's medical record), alone or in combination (including fixed-dose drug combination) with up to one additional of the following oral antidiabetic drugs: sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitors or alpha-glucosidase inhibitors~* Glycated haemoglobin (HbA1c) of greater than 7.5% to less than or less than or equal to 10.0% (greater than 58 mmol/mol to less than or equal to 86 mmol/mol)~Exclusion Criteria:~* History or presence of pancreatitis (acute or chronic)~* Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening~* Subjects presently classified as being in New York Heart Association Class IV~* Planned coronary, carotid or peripheral artery revascularisation known on the day of screening~* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. However, short term bolus insulin treatment for a maximum of 14 days prior to the day of screening is allowed~* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a pharmacologically pupil-dilated fundus examination performed by an ophthalmologist or an equally qualified health care provider (for example, optometrist) within the past 90 days prior to run-in

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semaglutide (Type: EXPERIMENTAL): Run-in period (12 weeks): subjects will be treated with metformin and insulin glargine (IGlar) U100.~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in will receive semaglutide for 52 weeks in addition to metformin and IGlar U100.~Metformin will be considered as background therapy during the trial.
- Insulin aspart (Type: ACTIVE_COMPARATOR): Run-in period (12 weeks): subjects will be treated with metformin and insulin IGlar U100.~Treatment period: Participants who are not in glycaemic control (defined as HbA1c of more than or equal to 7.5% to less than or equal to 10%) after run-in receive insulin aspart for 52 weeks in addition to metformin and IGlar U100.~Metformin will be considered as background therapy during the trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).